Benchmark Reiterates Buy on Belite Bio, Maintains $57 Price Target
Portfolio Pulse from richadhand@benzinga.com
Benchmark analyst Bruce Jackson reiterates a Buy rating on Belite Bio (NASDAQ:BLTE) and maintains a $57 price target.
June 20, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson reiterates a Buy rating on Belite Bio and maintains a $57 price target.
The news directly mentions Belite Bio (NASDAQ:BLTE) and the Buy rating from Benchmark analyst Bruce Jackson. This reaffirmation of the Buy rating and the maintained $57 price target could positively impact the stock price in the short term as it indicates confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100